ARS Pharmaceuticals, Inc. (SPRY)
(Real Time Quote from BATS)
$13.07 USD
+0.07 (0.54%)
Updated Aug 15, 2024 12:44 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SPRY 13.07 +0.07(0.54%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
Other News for SPRY
Raymond James ups ARS to strong buy, cites FDA neffy approval
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Raymond James upgrades ARS Pharmaceuticals to Strong Buy on tailwinds
Starbucks picks new CEO, Google unveils Pixel 9: Tuesday Buzz